These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18597859)

  • 41. Serotonin exerts a direct modulatory role on bladder afferent firing in mice.
    Konthapakdee N; Grundy L; O'Donnell T; Garcia-Caraballo S; Brierley SM; Grundy D; Daly DM
    J Physiol; 2019 Nov; 597(21):5247-5264. PubMed ID: 31520534
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 5-HT(3) receptors: role in disease and target of drugs.
    Walstab J; Rappold G; Niesler B
    Pharmacol Ther; 2010 Oct; 128(1):146-69. PubMed ID: 20621123
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human-derived gut microbiota modulates colonic secretion in mice by regulating 5-HT
    Bhattarai Y; Schmidt BA; Linden DR; Larson ED; Grover M; Beyder A; Farrugia G; Kashyap PC
    Am J Physiol Gastrointest Liver Physiol; 2017 Jul; 313(1):G80-G87. PubMed ID: 28408644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Direct interaction of the resistance to inhibitors of cholinesterase type 3 protein with the serotonin receptor type 3A intracellular domain.
    Nishtala SN; Mnatsakanyan N; Pandhare A; Leung C; Jansen M
    J Neurochem; 2016 May; 137(4):528-38. PubMed ID: 26875553
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Importance of recognition loops B and D in the activation of human 5-HT₃ receptors by 5-HT and meta-chlorophenylbiguanide.
    Michaelson SD; Paulsen IM; Kozuska JL; Martin IL; Dunn SM
    Neuropharmacology; 2013 Oct; 73():398-403. PubMed ID: 23810831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 47. 5-HT3 receptors in the CNS: 3B or not 3B?
    van Hooft JA; Yakel JL
    Trends Pharmacol Sci; 2003 Apr; 24(4):157-60. PubMed ID: 12707000
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Immunolabelling of the 5-HT 3B receptor subunit in the central and peripheral nervous systems in rodents.
    Doucet E; Latrémolière A; Darmon M; Hamon M; Emerit MB
    Eur J Neurosci; 2007 Jul; 26(2):355-66. PubMed ID: 17650111
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor.
    Wetzel CH; Hermann B; Behl C; Pestel E; Rammes G; Zieglgänsberger W; Holsboer F; Rupprecht R
    Mol Endocrinol; 1998 Sep; 12(9):1441-51. PubMed ID: 9731711
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Co-expression of the 5-HT3B serotonin receptor subunit alters the biophysics of the 5-HT3 receptor.
    Hapfelmeier G; Tredt C; Haseneder R; Zieglgänsberger W; Eisensamer B; Rupprecht R; Rammes G
    Biophys J; 2003 Mar; 84(3):1720-33. PubMed ID: 12609874
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 5-HT3 Receptors: A Potential Therapeutic Target for Epilepsy.
    Zhao H; Lin Y; Chen S; Li X; Huo H
    Curr Neuropharmacol; 2018; 16(1):29-36. PubMed ID: 28486926
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The serotonin 5-HT3 receptor: a novel neurodevelopmental target.
    Engel M; Smidt MP; van Hooft JA
    Front Cell Neurosci; 2013; 7():76. PubMed ID: 23761731
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterisation of 5-HT3C, 5-HT3D and 5-HT3E receptor subunits: evolution, distribution and function.
    Holbrook JD; Gill CH; Zebda N; Spencer JP; Leyland R; Rance KH; Trinh H; Balmer G; Kelly FM; Yusaf SP; Courtenay N; Luck J; Rhodes A; Modha S; Moore SE; Sanger GJ; Gunthorpe MJ
    J Neurochem; 2009 Jan; 108(2):384-96. PubMed ID: 19012743
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists.
    Wolf H
    Scand J Rheumatol Suppl; 2000; 113():37-45. PubMed ID: 11028830
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cancer chemotherapy-induced nausea and vomiting: role of mediators, development of drugs and treatment methods.
    Mahesh R; Perumal RV; Pandi PV
    Pharmazie; 2005 Feb; 60(2):83-96. PubMed ID: 15739895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Different efficacy of specific agonists at 5-HT3 receptor splice variants: the role of the extra six amino acid segment.
    Niemeyer MI; Lummis SC
    Br J Pharmacol; 1998 Feb; 123(4):661-6. PubMed ID: 9517385
    [TBL] [Abstract][Full Text] [Related]  

  • 57. From Chemotherapy-Induced Emesis to Neuroprotection: Therapeutic Opportunities for 5-HT3 Receptor Antagonists.
    Fakhfouri G; Mousavizadeh K; Mehr SE; Dehpour AR; Zirak MR; Ghia JE; Rahimian R
    Mol Neurobiol; 2015 Dec; 52(3):1670-1679. PubMed ID: 25377794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The molecular basis of the structure and function of the 5-HT3 receptor: a model ligand-gated ion channel (review).
    Reeves DC; Lummis SC
    Mol Membr Biol; 2002; 19(1):11-26. PubMed ID: 11989819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current experience with 5-HT3 receptor antagonists in fibromyalgia.
    Späth M
    Rheum Dis Clin North Am; 2002 May; 28(2):319-28. PubMed ID: 12122920
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility.
    Gershon MD
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():3-14. PubMed ID: 15521849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.